CureVac NV (CureVac NV) Equity-to-Asset : 0.66 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CureVac NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $563.73 Mil. CureVac NV's Total Assets for the quarter that ended in Dec. 2023 was $859.60 Mil. Therefore, CureVac NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.66.

The historical rank and industry rank for CureVac NV's Equity-to-Asset or its related term are showing as below:

CVAC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.33 Med: 0.53 Max: 0.66
Current: 0.66

During the past 6 years, the highest Equity to Asset Ratio of CureVac NV was 0.66. The lowest was -0.33. And the median was 0.53.

CVAC's Equity-to-Asset is ranked worse than
50.54% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs CVAC: 0.66

CureVac NV Equity-to-Asset Historical Data

The historical data trend for CureVac NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Equity-to-Asset Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.33

0.47

0.59

0.62

0.66

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.62	0.73	0.72	0.72	0.66

Competitive Comparison of CureVac NV's Equity-to-Asset

For the Biotechnology subindustry, CureVac NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CureVac NV's Equity-to-Asset falls into.

CureVac NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CureVac NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	563.731	/	859.595
	=	0.66

CureVac NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	563.731	/	859.595
	=	0.66

CureVac NV (NAS:CVAC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

CureVac NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of CureVac NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.